
Feature|Videos|July 9, 2025
Challenges for Bringing Orphan Drugs to Market
Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.
Advertisement
Episodes in this series

Not every product has a perfect data set at launch, and that’s where risk-sharing and value-based contracts come into play. This episode explores examples of how companies structure these agreements to address uncertainty, while still ensuring access. With large populations, like with osteoarthritis patients, cost-effectiveness becomes a primary lever.
Key discussion topics include:
- The tradeoff between pricing and access in large populations.
- Examples of successful risk-sharing and subscription models.
- How to position therapies for payer engagement despite imperfect data.
- Why targeting measurable, cost-driven outcomes is critical.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
5


